E-GEOD-11771 - Bortezomib resistance in THP-1 cell line

Submitted on 11 June 2008, released on 14 June 2008, last updated on 1 May 2014
Homo sapiens
Samples (6)
Array (1)
Protocols (10)
Bortezomib is a proteasome inhibitor used in severel different hematological malignancies. Resistance to this drug is still poorly understood. In order get more insight in the resistance mechanism, we developed several bortezomib resistant subclones of the THP-1 monocytic/macrophage cell line. On these subclones expression arrays were performed. We performed expression array three different bortezomib resistant subclones of the THP-1 cell line. The resistant subclones were spotted against the parental THP-1 wildtype cell line.
Experiment type
transcription profiling by array 
Serge Smeets <s.smeets@vumc.nl>, B Ylstra, BAC Dijkmans, C Lemos, CR Berkers, G Jansen, GJ Peters, GJL Kaspers, GL Scheffer, I v Zantwijk, J Cloos, JW v Heijden, K Debipersad, K Vojtekova, NE Franke, R Oerlemans, RJ Scheper, YG Assaraf
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BA, Scheper RJ, Jansen G.
Investigation descriptionE-GEOD-11771.idf.txt
Sample and data relationshipE-GEOD-11771.sdrf.txt
Processed data (1)E-GEOD-11771.processed.1.zip
Experiment designE-GEOD-11771.biosamples.png, E-GEOD-11771.biosamples.svg
Array designA-GEOD-2827.adf.txt